
13 November 2026
Incanthera plc
("Incanthera" or the "Company")
Result of AGM 2026
Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology, announces that at its AGM held on 13 November 2026 all resolutions were duly passed.
The Directors of the Company accept responsibility for the content of this announcement.
For further information please contact:
|
Incanthera plc Stuart Robertson, CEO Laura Brogden, CFO & Company Secretary |
Via Vigo Consulting |
|
|
|
|
Cairn Financial Advisers LLP (Aquis Exchange Corporate Adviser) Jo Turner / Liam Murray / Ed Downes |
+44 (0) 20 7213 0880 |
|
|
|
|
Stanford Capital Partners Ltd (Broker) Patrick Claridge / Bob Pountney |
+44 (0) 20 7628 5582 |
|
|
|
|
Vigo Consulting (Financial PR and Investor Relations) Jeremy Garcia / Rozi Morris |
+44 (0) 20 7390 0230 incanthera@vigoconsulting.com |
Notes to Editors
About Incanthera plc
Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology, delivering treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy.
Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform.
The Company's current focus is Skin + CELL, Incanthera’s unique luxury skincare brand in a range of dermatological applications to meet currently unmet needs in the skincare market.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
About Skin + CELL
Skin + CELL is Incanthera's luxury skincare brand, launched in August 2025. Our ground-breaking formulation and delivery expertise brings scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.
Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.
Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.